Is it essential to use fiducial markers during cone-beam CT-based radiotherapy for prostate cancer patients?

To compare soft-tissue cone-beam computed tomography (CBCT-P) and fiducial marker (CBCT-FM)-based image guided radiotherapy in prostate cancer patients.

Sixteen prostate cancer patients were treated with volumetric modulated arc therapy. Manual alignment using CBCT-P and CBCT-FM was performed for each patient. Couch shifts were calculated and compared between methods in the left-right (x), superior-inferior (y), and anterior-posterior (z) directions.

CBCT-P and CBCT-FM alignments were compared using 252 scans from the 16 patients. Mean displacement from zero was 2.4 ± 1.3, 1.7 ± 1.2, and 1.8 ± 1.1 mm for CBCT-P and 2.3 ± 1.3, 1.7 ± 1.1 and 1.8 ± 1.1 mm for CBCT-FM in the x, y and z directions, respectively. There was no difference in median displacement between CBCT-P and CBCT-FM; however, there was a significant positive correlation between CBCT-P- and CBCT-FM-based displacements in the x (r = 0.881; p < 0.001), y (r = 0.789; p < 0.001) and z (r = 0.856; p < 0.001) directions by linear regression analysis. Systematic deviations within each group were <1 mm; however, random and systematic errors were similar in the x and y directions but larger in the z direction.

Our study demonstrated that CBCT-FM was not superior to CBCT-P for image-guided radiotherapy in prostate cancer patients.

Japanese journal of radiology. 2016 Oct 11 [Epub ahead of print]

Berna A Yildirim, Cem Onal, Yemliha Dolek

Department of Radiation Oncology, Baskent University Faculty of Medicine, 01120, Adana, Turkey., Department of Radiation Oncology, Baskent University Faculty of Medicine, 01120, Adana, Turkey. .

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe